FDA

Dear Research Advocate, On Tuesday, I had the great honor of attending the bill signing for the 21st Century Cures Act (21stCC). It was particularly meaningful that this bill crossed the finish line during Vice President Biden’s tenure. His determination to deliver other families from the cancer tragedy experienced by his own lent a special strength to our collective efforts over a protracted period of congressional debate. If we continue to channel the Vice President’s level of commitment and determination, we can ensure that achieving faster medical progress remains at the forefront of national priorities. As you know (but it never hurts to reaffirm), it is important, but not sufficient,...
Dear Research Advocate, As we prepare to celebrate Thanksgiving, it is fitting to thank our public health workforce for their tireless efforts on our behalf every day of the year. Monday marked the official Public Health Thank You Day (PHTYD), but it is ongoing. This year’s effort has been extraordinary, with more than 50 organizations partnering with us to get the word out. For the first time since we launched PHTYD in 2005, Congress officially joined the effort. As I mentioned last week, the co-chairs of the House Public Health Caucus introduced a resolution supporting PHTYD. Online, more than 1,000 organizations and individuals participated, including federal officials from HHS and DOD,...
Watch the videos from each panel, read the transcript , view the photo gallery and read the WebMD live recap . “The biomedical research enterprise underpins the health of the nation and much of the world, and is in dire need of substantial infusion to meet the great medical needs of our time,” said William N. Hait, M.D., Ph.D. , global head, Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, the keynote speaker at the 2016 National Health Research Forum, added that we’re losing time in addressing threats like the Zika virus, Ebola and cancer while waiting for funding to improve for biomedical research. The program, held Thursday,...
Partnerships between patient groups, industry, government and academia are accelerating the research and development of new treatments for rare diseases, many of which have no effective therapies. As a result of the Food and Drug Administration’s (FDA) Orphan Drug Designation, eligible companies receive incentives for product development such as tax credits for qualified clinical testing and new drugs are reaching patients sooner. Since 1983, more than 400 drugs and biologic products for rare diseases have been developed, far outpacing the number of products that were available some 40 years ago. Amyotrophic lateral sclerosis (ALS) is among the nearly 7,000 rare diseases where very few...
Dear Research Advocate: Earlier this week, the House passed an inadequate proposal for $622.1 million in emergency Zika funding, falling far short of the bipartisan Senate proposal of $1.1 billion passed this week, not to mention the President’s request of $1.9 billion. Appropriations subcommittee Chairman Cole (R-OK-04) has stated that subsequent Zika funding will come in the next appropriations cycle, but public health experts tell us we cannot wait. (This is especially true since the pattern of the last many years is for appropriations to go undetermined until almost calendar year end.) Summer months are approaching and half the continental U.S. is home to potential disease-carrying...
The first half of 2016 has already been a very busy year for the Food and Drug Administration as it finalized and published its new comprehensive set of tobacco deeming regulations, continued its implementation of a new food safety system in compliance with the Food Safety Modernization Act, and released a new set of pain medication guidelines related to opioid addiction and abuse. All of these developments have come under newly appointed FDA commissioner Robert Califf, M.D. His top priorities also include strengthening FDA’s workforce, improving medical product safety, and supporting the President’s National Cancer Moonshot Initiative and the Precision Medicine Initiative. Dr. Califf will...
Dear Research Advocate: In the multi-faceted context of discouraging new data that shows an increasing incidence of suicide, rapidly rising prescription drug abuse, and widespread pain and suffering due to the heroin epidemic, the House is working on legislation to address opioid abuse , approving more than a dozen bills that will be packaged and considered on the floor in early May. This is important bipartisan progress in combating challenges of frightening scope, extending beyond addressing addiction and abuse to effectively meeting the challenge of chronic pain. Even as we commit to working harder to activate what we know works in terms of prevention and treatment, we must learn much...
Dear Research Advocate: A report out this week by United Health Foundation concluded that an astonishing 72% of Americans have at least one of the five most impactful “unhealthy behaviors” (smoking, physical inactivity, insufficient sleep, excessive drinking or obesity). A White House report out this week quantifies the massive public health threat brought on by climate change and outlines the emerging issues, supporting evidence and the research required to curb these predicted effects. The need for improved public health is more evident then ever, and public health research is the best way to develop evidence-based, outcome-oriented interventions. Good thing it’s National Public Health...
President Obama’s decree proclaiming April 4 – 10 National Public Health Week focuses on several key objective: stemming the tide of infectious disease like Zika; improving access to healthcare domestically and globally; promoting healthy behaviors in adolescents; preventing opioid and illicit drug abuse; decreasing gun violence; addressing climate change-related health issues; and improving access to mental health resources. National Public Health week is an opportunity to reflect on the pivotal role public health research and practice play in advancing the wellbeing of Americans and populations across the globe, and recognize the individuals, organizations and agencies that carry out...
Increasing funding for federal health research agencies to respond to health threats, harnessing the power of precision medicine and other cutting-edge research and keeping the needs of the patient front and center, were some of the key points shared by Dr. Robert Califf, Commissioner of the Food and Drug Administration (FDA) and Senator Amy Klobuchar (D-MN) during Research!America’s 27th Annual Meeting of Members held at the Willard Intercontinental Hotel in Washington, D.C., on March 16. “I remain excited about and dedicated to direct involvement with consumers and patients,” said Dr. Califf. He emphasized that the FDA’s mission is not only to protect safety and promote innovation but to...

Pages

Sidebar Quote

America’s economic destiny lies in innovation, technology, science and research.
The Honorable John E. Porter